FDA asks weight loss drugs to bear warning against rare eye blindness: Are we too early to trust GLPs?

The US Food and Drug Administration (FDA) has directed weight loss drugs to bear warning labels about a potential risk of causing a rare eye complication or blindness called NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy). This includes drugs like Ozempic, Wegovy, Mounjaro, Zepbound and other GLP-1 medications used for treating diabetes and now obesity-related problems.As per reports, this disorder happens when the blood supply to the…
- EgyptEcuadorian fishermen sue US over mysterious boat strike
- Sudan10 killed as drone strafes South Kordofan gold mine
- Saudi ArabiaLibya's eastern government suspects drone attack caused explosion on Russian ship at Benghazi port
- OmanForum examines sustainability of projects
- UAESaudi Arabia's new 15% tax: Who will pay and who is exempt?
- QatarQatar strongly condemns Iranian attack on civilian industrial facility in Bahrain
- BahrainMeet the ‘Vampire Camel’
- IndiaDelegates from 16 countries attend national conference of AITUC



